Stockreport

Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating) [Seeking Alpha]

Scholar Rock Holding Corporation  (SRRK) 
Last scholar rock holding corporation earnings: 11/12 07:30 am Check Earnings Report
PDF SRRK's Apitegromab achieved strong phase 3 results in spinal muscular atrophy, showing meaningful motor function gains and robust safety as an add-on therapy. The rec [Read more]